DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Krop I, Johnston S, Mayer IA et al.
The FERGI phase II study of the PI3 K inhibitor pictilisib (GDC-0941) plus fulvestrant vs. fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)- resistant advanced or metastatic breast cancer. San Antonio Breast Cancer Symposium 2014; Abstract No. S2–02.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.